Submitted:
06 November 2024
Posted:
07 November 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Patient Characteristics
2.2. Hospital Characteristics
2.3. Ethics
2.4. Outcome Measurements
2.5. Statistical Analysis
3. Results
3.1. Hospital Characteristics
3.2. Predicted Risk Model
3.3. Threshold of the Learning Curve
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Remon, J.; Soria, J.C.; Peters, S.; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: An update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann. Oncol. 2021, 32, 1637–1642. [Google Scholar] [PubMed]
- Rocco, G.; Internullo, E.; Cassivi, S.D.; Van Raemdonck, D.; Ferguson, M.K. The variability of practice in minimally invasive thoracic surgery for pulmonary resections. Thorac. Surg. Clin. 2008, 18, 235–247. [Google Scholar] [CrossRef] [PubMed]
- Vansteenkiste, J.; Crinò, L.; Dooms, C.; Douillard, J.Y.; Faivre-Finn, C.; Lim, E.; Rocco, G.; Senan, S.; van Schil, P.; Veronesi, G.; et al. 2nd ESMO Consensus Conference on Lung Cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 2014, 25, 1462–1474. [Google Scholar] [CrossRef]
- Wilson-Smith, A.R.; Anning, N.; Muston, B.; et al. learning curve of the robotic-assisted lobectomy —a systematic review and meta-analysis. Ann Cardiothorac Surg 2023, 12, 1–8. [Google Scholar] [CrossRef]
- Soomro, N.A.; Hashimoto, D.A.; Porteous, A.J.; et al. Systematic review of learning curves in robot-assisted surgery. BJS Open 2020, 4, 27–44. [Google Scholar] [CrossRef]
- Power, A.D.; D’Souza, D.M.; Mofatt Bruce, S.D.; Merritt, R.E.; Kneuertz, P.J. DefIning the learning curve of robotic thoracic surgery: what does it take? Surgical Endoscopy 2019. [CrossRef]
- Seely, A.J.E.; Ivanovic, J.; Threader, J.; et al. Systematic Classification of Morbidity and Mortality After Thoracic Surgery. Ann Thorac Surg 2010, 90, 936–942. [Google Scholar] [CrossRef]
- World Health Organization. International Statistical Classification of Diseases and Related Health Problems 10th Revision. Available online: http://apps.who.int/classifications/icd10/browse/2016/en (accessed on 1 March 2016).
- Iezzoni, L.I. Assessing quality using administrative data. Ann. Intern. Med. 1997, 127 Pt 2, 666–674. [Google Scholar] [CrossRef]
- Travis, W.D.; Brambilla, E.; Müller-Hermelink, H.K.; Harris, C.C. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart; IARC Press: Lyon, France, 2004. [Google Scholar]
- Charlson, M.; Szatrowski, T.P.; Peterson, J.; Gold, J. Validation of a combined comorbidity index. J. Clin. Epidemiol. 1994, 47, 1245–1251. [Google Scholar] [CrossRef]
- Steyerberg, E.W. Clinical Prediction Models: A Practical Approach to Development, Validation and Updating; Springer: New York, NY, USA, 2009. [Google Scholar] [CrossRef]
- Rogers, C.A.; Reeves, B.C.; Caputo, M.; et al. Control chart methods for monitoring cardiac surgical performance and their interpretation. J Thorac Cardiovasc Surg 2004, 128, 811–819. [Google Scholar] [CrossRef] [PubMed]
- Bhatt, A.; George, A.; Mehta, S. CRS and HIPEC for PMP-Use of the LC-CUSUM to determine the number of procedures required to attain a minimal level of proficiency in delivering the combined modality treatment. Indian J. Surg. Oncol. 2017, 8, 533–539. [Google Scholar] [CrossRef]
- Steiner, S.H.; Jones, M. Risk-adjusted survival time monitoring with an updating exponentially weighted moving average (EWMA) control chart. Stat. Med. 2010, 29, 444–454. [Google Scholar] [CrossRef] [PubMed]
- Song, G.; Sun, X.; Miao, S.; Li, S.; et al. Learning curve for robot-assisted lobectomy of lung cancer. J Thorac Dis 2019, 11, 2431–2437. [Google Scholar] [CrossRef] [PubMed]
- Baldonado, J.J.A.; Amaral, M.; Garrett, J.; et al. Credentialing for robotic lobectomy: what is the learning curve? A retrospective analysis of 272 consecutive cases by a single surgeon. Journal of Robotic Surgery 2019, 13, 663–669. [Google Scholar] [CrossRef]
- Le Gaca, C.; Gonde’ b, H.; Gillibert, A.; et al. Medico-economic impact of robot-assisted lung segmentectomy: what is the cost of the learning curve ? Interactive CardioVascular and Thoracic Surgery 2020, 30, 255–262. [Google Scholar] [CrossRef] [PubMed]
- Yang, M.Z.; Ren-Chun Lai Abbas, A.E.; et al. learning curve of robotic portal lobectomy for pulmonary neoplasms: A prospective observational study. Thorac Cancer. 2021, 12, 1431–1440. [Google Scholar] [CrossRef]
- Bernard, A.; Cottenet, J.; Pagès, P.B.; Quantin, C. Mortality and failure-to-rescue major complication trends after lung cancer surgery between 2005 and 2020: a nationwide population-based study. BMJ Open 2023, 13, e075463. [Google Scholar] [CrossRef]
- Bernard, A.; Cottenet, J.; Pages, P.B.; Quantin, C. Diffusion of Minimally Invasive Approach for Lung Cancer Surgery in France: A Nationwide, Population-Based Retrospective Cohort Study. Cancers 2023, 15, 3283. [Google Scholar] [CrossRef]
- Zhang, Y.; Liu, S.; Han, Y.; et al. Robotic Anatomical Segmentectomy: An Analysis of the Learning Curve. Ann Thorac Surg 2019, 107, 1515–1522. [Google Scholar] [CrossRef]
- Fahim, C.; Hanna, W.; Waddell, T.; et al. Robotic-assisted thoracoscopic surgery for lung resection: the first Canadian series. J can chir. 2017, 60, 260–265. [Google Scholar] [CrossRef] [PubMed]
- Bernard, A.; Cottenet, J.; Quantin, C. Is the Validity of Logistic Regression Models Developed with a National Hospital Database Inferior to Models Developed from Clinical Databases to Analyze Surgical Lung Cancers? Cancers 2024, 16, 734. [Google Scholar] [CrossRef] [PubMed]
- Etienne, H.; Pagès, P.B.; Iquille, J.; et al. Impact of surgical approach on 90-day mortality after lung resection for non-small cell lung cancer in high-risk operable patients. ERJ Open Res 2024, 10, 00653–2023. [Google Scholar] [CrossRef] [PubMed]


| 2019 | 2020 | 2021 | 2022 | p-value | |
| n=195 | n=747 | n=1,197 | n=1,567 | ||
| Age (years) | 67.24 (9) | 66.7 (9.3) | 67.2 (8.8) | 66.96 (8.8) | 0.769 |
| Sex | |||||
| Male | 117 (60.0%) | 412 (55.2%) | 655 (54.7%) | 864 (55.1%) | 0.588 |
| Female | 78 (40.0%) | 335 (44.8%) | 542 (45.3%) | 703 (44.9%) | |
| Pulmonary disease | |||||
| No | 146 (74.9%) | 545 (73.0%) | 863 (72.1%) | 1,136 (72.5%) | 0.870 |
| Yes | 49 (25.1%) | 202 (27.0%) | 334 (27.9%) | 431 (27.5%) | |
| Heart disease | |||||
| No | 162 (83.1%) | 634 (84.9%) | 1,031 (86.1%) | 1,349 (86.1%) | 0.596 |
| Yes | 33 (16.9%) | 113 (15.1%) | 166 (13.9%) | 218 (13.9%) | |
| Peripheral vascular | |||||
| No | 183 (93.8%) | 681 (91.2%) | 1,097 (91.6%) | 1,424 (90.9%) | 0.542 |
| Yes | 12 (6.2%) | 66 (8.8%) | 100 (8.4%) | 143 (9.1%) | |
| Neurological disease | |||||
| No | 189 (96.9%) | 711 (95.2%) | 1,146 (95.7%) | 1,499 (95.7%) | 0.758 |
| Yes | 6 (3.1%) | 36 (4.8%) | 51 (4.3%) | 68 (4.3%) | |
| Cirrhosis | |||||
| No | 195 (100.0%) | 740 (99.1%) | 1,181 (98.7%) | 1,559 (99.5%) | 0.061 |
| Yes | 0 (0.0%) | 7 (0.9%) | 16 (1.3%) | 8 (0.5%) | |
| Renal disease | |||||
| No | 189 (96.9%) | 712 (95.3%) | 1,156 (96.6%) | 1,519 (96.9%) | 0.250 |
| Yes | 6 (3.1%) | 35 (4.7%) | 41 (3.4%) | 48 (3.1%) | |
| Metabolic disease | |||||
| No | 161 (82.6%) | 646 (86.5%) | 1,014 (84.7%) | 1,342 (85.6%) | 0.481 |
| Yes | 34 (17.4%) | 101 (13.5%) | 183 (15.3%) | 225 (14.4%) | |
| Anemia | |||||
| No | 163 (83.6%) | 649 (86.9%) | 1,002 (83.7%) | 1,313 (83.8%) | 0.216 |
| Yes | 32 (16.4%) | 98 (13.1%) | 195 (16.3%) | 254 (16.2%) | |
| Infectious disease | |||||
| No | 194 (99.5%) | 747 (100.0%) | 1,190 (99.4%) | 1,563 (99.7%) | 0.145 |
| Yes | 1 (0.5%) | 0 (0.0%) | 7 (0.6%) | 4 (0.3%) | |
| Hematologic disease | |||||
| No | 190 (97.4%) | 729 (97.6%) | 1,166 (97.4%) | 1,536 (98.0%) | 0.736 |
| Yes | 5 (2.6%) | 18 (2.4%) | 31 (2.6%) | 31 (2.0%) | |
| Other disease | |||||
| No | 135 (69.2%) | 430 (57.6%) | 695 (58.1%) | 998 (63.7%) | <0.001 |
| Yes | 60 (30.8%) | 317 (42.4%) | 502 (41.9%) | 569 (36.3%) | |
| Other treatment | |||||
| No | 182 (93.3%) | 645 (86.3%) | 1,046 (87.4%) | 1,439 (91.8%) | <0.001 |
| Yes | 13 (6.7%) | 102 (13.7%) | 151 (12.6%) | 128 (8.2%) | |
| Charlson score | |||||
| 0 | 82 (42.1%) | 283 (37.9%) | 445 (37.2%) | 614 (39.2%) | 0.028 |
| 1 | 26 (13.3%) | 69 (9.2%) | 130 (10.9%) | 195 (12.4%) | |
| 2 | 24 (12.3%) | 88 (11.8%) | 120 (10.0%) | 190 (12.1%) | |
| ≥3 | 63 (32.3%) | 307 (41.1%) | 502 (41.9%) | 568 (36.2%) | |
| Pulmonary resection | |||||
| limited | 8 (4.1%) | 21 (2.8%) | 37 (3.1%) | 36 (2.3%) | 0.382 |
| lobectomy | 187 (95.9%) | 726 (97.2%) | 1,160 (96.9%) | 1,531 (97.7%) | |
| Clavien Dindo | |||||
| None | 118 (60.5%) | 426 (57.0%) | 698 (58.3%) | 938 (59.9%) | 0.048 |
| Group ≤ II | 25 (12.8%) | 138 (15.0%) | 196 (16.3%) | 241 (15.4%) | |
| Group IIIa | 21 (10.8%) | 55 (7.4%) | 108 (9.0%) | 132 (8.4%) | |
| Group IIIb | 6 (3.1%) | 21 (2.8%) | 36 (3.0%) | 57 (3.6%) | |
| Group IVa | 2 (1.0%) | 23 (3.1%) | 27 (2.3%) | 40 (2.6%) | |
| Group IVb | 20 (10.3%) | 73 (9.8%) | 109 (9.1%) | 150 (9.6%) | |
| Group V | 3 (1.5%) | 11 (1.5%) | 23 (1.9%) | 9 (0.6%) |
| Year | |||||
| 2019 | 2020 | 2021 | 2022 | p-value | |
| Nb of patients | 195 | 747 | 1 197 | 1 567 | |
| Nb of hospitals | 29 | 50 | 43 | 64 | |
| Nb of hospitals >25 procedure | 20 | 25 | 25 | 28 | |
| Type of hospital | |||||
| Non academic | 37 (19.0%) | 114 (15.3%) | 128 (10.7%) | 161 (10.3%) | <0.001 |
| Academic | 30 (15.4%) | 264 (35.3%) | 548 (45.8%) | 733 (46.8%) | |
| Private non-profit | 53 (27.2%) | 127 (17.0%) | 203 (17.0%) | 234 (14.9%) | |
| Private for profit | 75 (38.5%) | 242 (32.4%) | 318 (26.6%) | 439 (28.0%) | |
| Total Hospital- volume $ | 187 (222) | 184 (189) | 236 (210) | 263 (268) | <0.001 |
| Hospital-Volume RA $ | 13 (6.3) | 44 (29.7) | 69 (39.6) | 72 (52) | <0.001 |
| Clavien Dindo > II | |||||
| Observed$$ | 0.15 [0-0.41] | 0.24[0.19-0.32] | 0.25[0.19-0.33] | 0.27[0.17-0.37] | |
| Predicted$$ | 0.21[0.12-0.32] | 0.22[0.15-0.32] | 0.25[0.18-0.32] | 0.24[0.18-0.356] | |
| Threshold learning curve | |||
| No | Yes | p-value | |
| n=1,489 | n=1,870 | ||
| Pulmonary resection | |||
| limited | 39 (2.6%) | 43 (2.3%) | 0.551 |
| Lobectomy | 1,450 (97.4%) | 1,827 (97.7%) | |
| Clavien-Dindo | |||
| No | 847 (56.9%) | 1,136 (60.7%) | <0.001 |
| ≤ II | 231 (15.5%) | 317 (17.0%) | |
| IIIa | 115 (7.7%) | 170 (9.1%) | |
| IIIb | 56 (3.8%) | 54 (2.9%) | |
| IVa | 45 (3.0%) | 41 (2.2%) | |
| IVb | 176 (11.8%) | 131 (7.0%) | |
| V | 19 (1.3%) | 21 (1.1%) | |
| Fistula | |||
| No | 1,475 (99.1%) | 1,857 (99.3%) | 0.429 |
| Yes | 14 (0.9%) | 13 (0.7%) | |
| Empyema | |||
| No | 1,483 (99.6%) | 1,859 (99.4%) | 0.452 |
| Yes | 6 (0.4%) | 11 (0.6%) | |
| Pneumonia | |||
| No | 1,392 (93.5%) | 1,729 (92.5%) | 0.250 |
| Yes | 97 (6.5%) | 141 (7.5%) | |
| Hemorraghe | |||
| No | 1,420 (95.4%) | 1,812 (96.9%) | 0.021 |
| Yes | 69 (4.6%) | 58 (3.1%) | |
| Pleural effusion | |||
| No | 1,250 (83.9%) | 1,625 (86.9%) | 0.016 |
| Yes | 239 (16.1%) | 245 (13.1%) | |
| Respiratory insuffiency | |||
| No | 1,332 (89.5%) | 1,756 (93.9%) | <0.001 |
| Yes | 157 (10.5%) | 114 (6.1%) | |
| ARDS | |||
| No | 1,426 (95.8%) | 1,831 (97.9%) | <0.001 |
| Yes | 63 (4.2%) | 39 (2.1%) | |
| Arrthymia | |||
| No | 1,322 (88.8%) | 1,654 (88.4%) | 0.761 |
| Yes | 167 (11.2%) | 216 (11.6%) | |
| Myocardial infarction | |||
| No | 1,478 (99.3%) | 1,864 (99.7%) | 0.090 |
| Yes | 11 (0.7%) | 6 (0.3%) | |
| Heart failure | |||
| No | 1,461 (98.1%) | 1,858 (99.4%) | 0.001 |
| Yes | 28 (1.9%) | 12 (0.6%) | |
| Acute ischemia | |||
| No | 1,489 (100.0%) | 1,864 (99.7%) | 0.029 |
| Yes | 0 (0.0%) | 6 (0.3%) | |
| Pulmonary embolism | |||
| No | 1,464 (98.3%) | 1,857 (99.3%) | 0.007 |
| Yes | 25 (1.7%) | 13 (0.7%) | |
| Stroke | |||
| No | 1,470 (98.7%) | 1,848 (98.8%) | 0.794 |
| Yes | 19 (1.3%) | 22 (1.2%) | |
| Denutrition | |||
| No | 1,406 (94.4%) | 1,780 (95.2%) | 0.321 |
| Yes | 83 (5.6%) | 90 (4.8%) | |
| Sepsis | |||
| No | 1,429 (96.0%) | 1,791 (95.8%) | 0.778 |
| Yes | 60 (4.0%) | 79 (4.2%) | |
| 30-day mortality | |||
| No | 1,470 (98.7%) | 1,849 (98.9%) | 0.685 |
| Yes | 19 (1.3%) | 21 (1.1%) | |
| Reoperation | |||
| No | 1,486 (99.8%) | 1,865 (99.7%) | 0.697 |
| Yes | 3 (0.2%) | 5 (0.3%) | |
| Prolonged length of Stay | |||
| <14 days | 1,350 (90.6%) | 1,703 (90.7%) | 0.939 |
| >=14 days | 140 (9.4%) | 175 (9.3%) | |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).